Leader Biomedical announces acquisition of International Orthopaedics Holding GmbH
Amsterdam | Geisingen | 27 February 2018Leader Biomedical is pleased to announce the phased acquisition of International Orthopaedics Holding GmbH (International Orthopaedics), a manufacturer and distributor of orthopaedic implants based in Geisingen, Germany. The companies have entered into a notarial deed on the 20th of February, 2018. This phased acquisition is in line with Leader Biomedical’s vision to expand its therapeutic solutions offering in Germany and to enhance its infrastructure for global operations.
“I am excited to partner with Leader Biomedical. We see that with the support of Leader Biomedical’s team, we will be able to increase our offerings of orthopaedic implants to our customers to include cements, bone grafts, and additional biomaterials for spine and sports. Leader Biomedical’s investments into International Orthopaedics will further help us strengthen our position on the German market in offering value-added services to our customers,” shares Marc Bittenbinder, Founder and Managing Director of International Orthopaedics Holding GmbH.
“We are eager to welcome International Orthopaedics to the Leader Biomedical Group,” says Mr. Leo Liyeung, Group Executive Director of Leader Biomedical Group. “International Orthopaedics has been a reliable partner for Leader Biomedical from the start. Their strengths are highly complementary to ours, and together, we can create myriad opportunities for further growth.”
Customers in Germany will benefit from International Orthopaedics’ infrastructure, complemented by Leader Biomedical’s solutions portfolio, next generation technologies, and dedicated customer service. International Orthopaedics’ current portfolio of orthopaedic implants will be supplemented with C-ment®, a high-quality line of PMMA bone cements with and without gentamycin, the X-Grip® system, a leading ACL reconstruction solution, eTiss® allografts processed with Leader Biomedical’s proprietary eCOO® Technology using supercritical carbon dioxide, as well as the Ossfinity® and OssGro® line of synthetic grafts produced with MBCP™ Technology, a proprietary method which combines 60% HA and 40% βTCP.
“The acquisition of International Orthopaedics is consistent with Leader Biomedical’s ambitions to expand our on-ground operations in Europe. We are pursuing strategic opportunities in catering to local healthcare establishments and in providing affordable healthcare services with International Orthopaedics. We shall be investing in the infrastructure of International Orthopaedics to integrate Leader Biomedical’s supply chain and after sales capabilities. Over the next years, we envision to further develop customer management in the DACH region through Geisingen“, adds Basil Babychan, Group Business Director Leader Biomedical Group.
This acquisition reaffirms Leader’s vision for the DACH region after the discontinuation of the partnership with aap Joints GmbH in 2017 and an increased investment into BioTiss GmbH in early 2018. The acquisition of International Orthopaedics is the latest investment by Leader Biomedical and follows its earlier expansions into India, Brazil, Russia, and Malaysia in 2016 and the U.S.A. in 2017.
About International Orthopaedics Holding GmbH: “Innovation in Orthopaedics”
International Orthopaedics Holding GmbH is dedicated to safety in procedures by providing innovation and performance to patients as well as offering education and great service support to healthcare professionals. IO Holding GmbH offers high performance implants and instruments from trusted, high-Quality German and other European manufacturers (www.io-holding.com)
About Leader Biomedical: “Extending Your Reach”
Leader Biomedical is committed to contributing to the betterment of the global healthcare community with proven solutions and continuous innovation, and extending the reach of patients and caregivers by improving global access to reliable, targeted therapeutic solutions and new technologies. Leader Biomedical’s portfolio offers therapeutic solutions; focusing on orthopaedic, dental, spine, trauma and sports medicine (www.leaderbiomedical.com)
Leader Biomedical Europe B.V.
Herikerbergweg 300, Diana Building
1101 CT Amsterdam
The Netherlands
Sandy Plat
Group Marketing & Communications Manager
+31 (0)6 2972 6530
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Leader Biomedical announces acquisition of International Orthopaedics Holding GmbH here
News-ID: 959800 • Views: …
More Releases from Leader Biomedical
First patient in Malaysia successfully treated with Urolastic™ - collaboration …
Urogyn B.V. and Leader Biomedical announce the first patient treated in Malaysia with Urolastic™– an innovative Urinary Stress Incontinence product that is exclusively offered by Leader Biomedical in India and APAC.
We are excited to announce that we have successfully introduced Urolastic™ in Malaysia and treated a female patient suffering from severe Stress Urinary Incontinence (SUI). The patient suffered from the condition, as a result of birth deficiencies and was…
ANVISA approval for EMCM facilitates the progress of Leader Biomedical operation …
6 April 2017- AMSTERDAM/SAO PAULO- Leader Biomedical is proud to announce that our manufacturing facility in Nijmegen, European Medical Contract Manufacturing B.V. (EMCM) has received approval by the Brazilian competent authority, Agência Nacional de Vigilância Sanitária (ANVISA). This approval follows the previously announced, ANVISA approval of our facilities in Brazil, Inovações Biológicas Comercial LTDA (Leader Biomedical Brazil), which validated the warehouse facilities and presence of technical staff, ensuring quality standards…
Leader Biomedical and Urogyn collaborate to bring innovative new procedure Urola …
10 January 2017- Amsterdam, The Netherlands- Urogyn B.V. and Leader Biomedical are proud to announce that Urolastic™ - an innovative Urinary Stress incontinence product - has been introduced into the product registration process in India. This marks the first step towards bringing a novel therapeutic solution to patients and caregivers in India.
Many women suffer from Stress Urinary Incontinence (SUI), radically affecting their quality of life due to restraining…
More Releases for Orthopaedics
Orthopaedics Market Size, Status and Forecast TO 2025
HTF Market Intelligence released a new research report of 99 pages on title 'Global Orthopaedics Market Size, Status and Forecast 2020-2025' with detailed analysis, forecast and strategies. The study covers key regions that includes North America, Europe or Asia and important players such as Johnson and Johnson, Czech state beauty, Szecker, Medtronic, Xerox Fai, NuVasive, Wright Medical, Orthofix, Globus Medical, Minimally Invasive Medical, Arthrex, Weigao, etc.
Get Free Sample Report +…
Orthopaedics Market Size, Share, Development by 2024
Market Research Report Store offers a latest published report on Orthopaedics Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report.
According to this study, over the next five years the Orthopaedics market will register a 4.5% CAGR in terms of revenue, the global market size will reach US$ 64050 million by 2024, from US$ 53640 million in 2019. In particular, this…
Combination Drugs Diagnostic Market Professional Survey Report By Product, Appli …
A report added to the rich database of Qurate Business Intelligence, titled “Global Combination Drugs Diagnostic Market Size, Status and Forecast 2025”, provides a 360-degree overview of the worldwide market. Approximations associated with the market values over the forecast period are based on empirical research and data collected through both primary and secondary sources. The authentic processes followed to exhibit various aspects of the market makes the data reliable in…
Combination Drugs Diagnostic Market 2018 Analysis The Global Key Players: Biomet …
Combination Drugs is Fixed-Dose Combination (FDC), it is a combination of two or more Active Pharmaceutical Ingredients (APIs), mixed to form a single drug. Combination Drugs is manufactured and sold in fixed doses format. Earlier Combination Drugs were developed for single disease treatment, but not have a wide variety of applications for treatment of various diseases. Combination Drugs Diagnostic is growing due to factors like; increase in the aged population…
Safe Orthopaedics SA (SAFOR) - Product Pipeline Analysis, 2017 Update
"The Report Safe Orthopaedics SA (SAFOR) - Product Pipeline Analysis, 2017 Update provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
Safe Orthopaedics SA (Safe Orthopaedics) is medical equipment company that manufactures and markets minimally invasive devices for spinal surgery. The companys product portfolio includes implants and surgical instruments. It offers modular cervical cages, percutaneous auto-correction screws, modular anchorage screws, percutaneous auto-correction…
curasan AG: New US subsidiary for orthopaedics
Kleinostheim, Germany, 18th February 2010 – curasan AG, listed in the General Standard of the Deutsche Börse AG (ISIN: DE 000 549 453 8), is commencing the sale, through a subsidiary, of its synthetic bone regeneration material Cerasorb® M Ortho in the United States.
The newly founded curasan Inc., with its headquarters in Massachusetts, is responsible for commercial and logistical management as well as marketing activities. This occurs in coordination with…